André Uddin

Aurinia Pharmaceuticals Inc (NASDAQ: AUPH)'s Voclosporin is about to begin Phase 3 trials for first-line treatment of lupus nephritis. The company could be an “ideal acquisition candidate once Phase 3 kicks off,” Mackie Research Capital’s André Uddin said in a report. Uddin...

Mackie Research has upgraded CARDIOME PHARMA CORP (NASDAQ: CRME) to Speculative Buy from Hold on its recent licensing of Xydalba (Dalbavancin) from Allergan plc Ordinary Shares (NYSE: AGN) for $13 million up front. The Potential Power Of Dalbavancin Cardiome will also pay undisclosed "additional...